English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Multidrug-Resistant Tuberculosis (MDR-TB) with bacillary resistance to at least isoniazid and rifampicin in vitro is a worldwide phenomenon. For MDR-TB second-line antibiotic agents that are more potent and more toxic must be used. . One of them is kanamycin given intravenously every day for six (6) months therapy. Kanamycin is nephrotoxic and can lead to hypokalemia. This study is carried out to know the comparison between the potasium level before and after kanamycin therapy (2, 4 and 6 months after therapy). This study is a cohort retrospective design, comprising 34 patients who had a potassium baseline before therapy in Moewardi Hospital, Surakarta from January 2011–August 2012. The characteristic data included: age, sex, weight and comorbidity. The potassium level after 2, 4 and 6 months post therapy was compared with the potassium data baseline using One Way ANOVA test with p 0.05. Hypokalemia occurred in 6 patients after 2 months therapy, 8 patients after 4 months therapy and 3 patients after 6 months therapy. There was a significant difference between the potassium level after 6 months therapy and potassium baseline. Further study should be continued to know the existence of hypokalemia among MDR-TB patients

KALIUM DI MULTIDRUG RESISTANCE TUBERKULOSIS DENGAN PENGOBATAN KANAMISIN (Potassium in Multidrug Resistance Tuberculosis with Kanamycin)